Literature DB >> 23218469

Search for α3β₂/₃γ2 subtype selective ligands that are stable on human liver microsomes.

Ojas A Namjoshi1, Zhi-jian Wang, Sundari K Rallapalli, Edward Merle Johnson, Yun-Teng Johnson, Hanna Ng, Joachim Ramerstorfer, Zdravko Varagic, Werner Sieghart, Samarpan Majumder, Bryan L Roth, James K Rowlett, James M Cook.   

Abstract

Selective modulation of specific benzodiazepine receptor (BzR) gamma amino butyric acid-A (GABA(A)) receptor ion channels has been identified as an important method for separating out the variety of pharmacological effects elicited by BzR-related drugs. Importantly, it has been demonstrated that both α2β(2/3)γ2 (α2BzR) and α3BzR (and/or α2/α3) BzR subtype selective ligands exhibit anxiolytic effects with little or no sedation. Previously we have identified several such ligands; however, three of our parent ligands exhibited significant metabolic liability in rodents in the form of a labile ester group. Here eight analogs are reported which were designed to circumvent this liability by utilizing a rational replacement of the ester moiety based on medicinal chemistry precedents. In a metabolic stability study using human liver microsomes, four compounds were found to undergo slower metabolic transformation, as compared to their corresponding ester analogs. These compounds were also evaluated in in vitro efficacy assays. Additionally, bioisostere 11 was evaluated in a rodent model of anxiety. It exhibited anxiolytic activity at doses of 10 and 100mg/kg and was devoid of sedative properties.
Copyright © 2012 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23218469      PMCID: PMC3529916          DOI: 10.1016/j.bmc.2012.10.057

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  31 in total

Review 1.  A new benzodiazepine pharmacology.

Authors:  H Möhler; J M Fritschy; U Rudolph
Journal:  J Pharmacol Exp Ther       Date:  2002-01       Impact factor: 4.030

2.  Molecular and neuronal substrate for the selective attenuation of anxiety.

Authors:  K Löw; F Crestani; R Keist; D Benke; I Brünig; J A Benson; J M Fritschy; T Rülicke; H Bluethmann; H Möhler; U Rudolph
Journal:  Science       Date:  2000-10-06       Impact factor: 47.728

3.  Effects of hippocampal injections of a novel ligand selective for the alpha 5 beta 2 gamma 2 subunits of the GABA/benzodiazepine receptor on Pavlovian conditioning.

Authors:  David J Bailey; Julie E Tetzlaff; James M Cook; Xiaohui He; Fred J Helmstetter
Journal:  Neurobiol Learn Mem       Date:  2002-07       Impact factor: 2.877

4.  Anxiolytic-like effects of 8-acetylene imidazobenzodiazepines in a rhesus monkey conflict procedure.

Authors:  Bradford D Fischer; Stephanie C Licata; Rahul V Edwankar; Zhi-Jian Wang; Shengming Huang; Xiaohui He; Jianming Yu; Hao Zhou; Edward M Johnson; James M Cook; Roman Furtmüller; Joachim Ramerstorfer; Werner Sieghart; Bryan L Roth; Samarpan Majumder; James K Rowlett
Journal:  Neuropharmacology       Date:  2010-08-18       Impact factor: 5.250

5.  Benzodiazepine actions mediated by specific gamma-aminobutyric acid(A) receptor subtypes.

Authors:  U Rudolph; F Crestani; D Benke; I Brünig; J A Benson; J M Fritschy; J R Martin; H Bluethmann; H Möhler
Journal:  Nature       Date:  1999-10-21       Impact factor: 49.962

6.  Oxadiazoles in medicinal chemistry.

Authors:  Jonas Boström; Anders Hogner; Antonio Llinàs; Eric Wellner; Alleyn T Plowright
Journal:  J Med Chem       Date:  2012-01-13       Impact factor: 7.446

7.  Sedative but not anxiolytic properties of benzodiazepines are mediated by the GABA(A) receptor alpha1 subtype.

Authors:  R M McKernan; T W Rosahl; D S Reynolds; C Sur; K A Wafford; J R Atack; S Farrar; J Myers; G Cook; P Ferris; L Garrett; L Bristow; G Marshall; A Macaulay; N Brown; O Howell; K W Moore; R W Carling; L J Street; J L Castro; C I Ragan; G R Dawson; P J Whiting
Journal:  Nat Neurosci       Date:  2000-06       Impact factor: 24.884

8.  HZ166, a novel GABAA receptor subtype-selective benzodiazepine site ligand, is antihyperalgesic in mouse models of inflammatory and neuropathic pain.

Authors:  Alessandra Di Lio; Dietmar Benke; Marie Besson; Jules Desmeules; Youssef Daali; Zhi-jian Wang; Rahul Edwankar; James M Cook; Hanns Ulrich Zeilhofer
Journal:  Neuropharmacology       Date:  2010-12-08       Impact factor: 5.250

9.  Novel positive allosteric modulators of GABAA receptors: do subtle differences in activity at alpha1 plus alpha5 versus alpha2 plus alpha3 subunits account for dissimilarities in behavioral effects in rats?

Authors:  Miroslav M Savić; Samarpan Majumder; Shengming Huang; Rahul V Edwankar; Roman Furtmüller; Srdan Joksimović; Terry Clayton; Joachim Ramerstorfer; Marija M Milinković; Bryan L Roth; Werner Sieghart; James M Cook
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2010-01-13       Impact factor: 5.067

10.  Diazepam-bound GABAA receptor models identify new benzodiazepine binding-site ligands.

Authors:  Lars Richter; Chris de Graaf; Werner Sieghart; Zdravko Varagic; Martina Mörzinger; Iwan J P de Esch; Gerhard F Ecker; Margot Ernst
Journal:  Nat Chem Biol       Date:  2012-03-25       Impact factor: 15.040

View more
  5 in total

1.  Pharmacological and antihyperalgesic properties of the novel α2/3 preferring GABAA receptor ligand MP-III-024.

Authors:  Bradford D Fischer; Raymond J Schlitt; Bryan Z Hamade; Sabah Rehman; Margot Ernst; Michael M Poe; Guanguan Li; Revathi Kodali; Leggy A Arnold; James M Cook
Journal:  Brain Res Bull       Date:  2017-03-04       Impact factor: 4.077

2.  GABAA Receptor Subtypes and the Abuse-Related Effects of Ethanol in Rhesus Monkeys: Experiments with Selective Positive Allosteric Modulators.

Authors:  Lais F Berro; Daniela Rüedi-Bettschen; Jemma E Cook; Lalit K Golani; Guanguan Li; Rajwana Jahan; Farjana Rashid; James M Cook; James K Rowlett; Donna M Platt
Journal:  Alcohol Clin Exp Res       Date:  2019-04-08       Impact factor: 3.455

3.  Improved Synthesis of Anxiolytic, Anticonvulsant and Antinociceptive α2/α3-GABA(A)ergic Receptor Subtype Selective Ligands as Promising Agents to Treat Anxiety, Epilepsy, as well as Neuropathic Pain.

Authors:  Guanguan Li; Lalit K Golani; Rajwana Jahan; Farjana Rashid; James M Cook
Journal:  Synthesis (Stuttg)       Date:  2018-10       Impact factor: 3.157

4.  Evaluation of the anti-conflict, reinforcing, and sedative effects of YT-III-31, a ligand functionally selective for α3 subunit-containing GABAA receptors.

Authors:  Zhiqiang Meng; Lais F Berro; Eileen K Sawyer; Daniela Rüedi-Bettschen; Jemma E Cook; Guanguan Li; Donna M Platt; James M Cook; James K Rowlett
Journal:  J Psychopharmacol       Date:  2019-10-31       Impact factor: 4.153

5.  Novel Benzodiazepine-Like Ligands with Various Anxiolytic, Antidepressant, or Pro-Cognitive Profiles.

Authors:  Thomas D Prevot; Guanguan Li; Aleksandra Vidojevic; Keith A Misquitta; Corey Fee; Anja Santrac; Daniel E Knutson; Michael Rajesh Stephen; Revathi Kodali; Nicolas M Zahn; Leggy A Arnold; Petra Scholze; Janet L Fisher; Bojan D Marković; Mounira Banasr; James M Cook; Miroslav Savic; Etienne Sibille
Journal:  Mol Neuropsychiatry       Date:  2019-01-23
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.